Syndax Pharmaceuticals Inc.

# Signal Note: Eventide Initiates $26M Position in SNDX Eventide's entry into Syndax signals confidence in entinostat, the company's lead HDAC inhibitor in Phase 2b for metastatic breast cancer (MBC) when combined with exemestane—a cheaper, less toxic alternative positioning to checkpoint inhibitors in HR+/HER2- disease. The timing suggests positioning ahead of near-term clinical readouts or regulatory milestones, likely 2024-2025, where positive efficacy/safety data could unlock partnership or approval pathways in a competitive endocrine therapy space.